Latest Share Chat

Venn Life Sciences Share News (VENN)

Venn Life Sciences Information

There is currently no data for VENN

Venn Life Sciences acquires Cardinal Systems

Tue, 05th Aug 2014 17:34

Venn Life Sciences, a clinical research organisation (CRO), announced on Tuesday the acquisition of Cardinal Systems SAS, a French CRO specialising in Data Management.The acquisition will allow Venn to extend its service of clinical trial management and resourcing solutions. The company will by September own 85.2% of the enlarged share capital of Cardinal.Venn has subscribed €200,000 of new ordinary shares and has purchased existing shares in Cardinal for €272,780.Venn's chief executive Tony Richardson said the acquisition "enhances our growth opportunities as a company as we can target a wider portfolio of studies and we have already encountered positive feedback from potential customers".JF

More News

23 Oct 2015 08:17

Venn Life Sciences signs EUR1m contract

(ShareCast News) - Venn Life Sciences has signed a €1m contract with a leading French biotech company. The AIM listed clinical research organisation announced the deal on Friday. The two-phase project is centred on acute T-cell leukaemia, and will cover multiple regions including France, the UK and

23 Oct 2015 06:42

Venn Life Sciences Wins Leukaemia Project Worth Over EUR1 Million

19 Oct 2015 07:12

Venn Life Sciences Appoints Kinesis Pharma's Groen Executive Director

22 Sep 2015 15:51

Venn Life posts narrow interim loss, acquires Kinesis

(ShareCast News) - Clinical trial services provider Venn Life Sciences posted a narrower interim pre-tax loss and has agreed to acquire Kinesis Pharma BV. In the six months to the end of June, the London-listed company saw its pre-tax loss narrow from €987,000 (£716,000) to €259,000, while revenue a

22 Sep 2015 08:35

Venn Life Sciences To Buy Kinesis Pharma As Interim Loss Narrows (ALLISS)

13 Aug 2015 11:35

Venn Life Sciences reports strong first-half trading

(ShareCast News) - Venn Life sciences said it has had a strong first half, with revenues up 170% on the previous year. In a very brief trading update, the company, which provides clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, reported

13 Aug 2015 06:45